Cargando…
Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological mark...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375181/ https://www.ncbi.nlm.nih.gov/pubmed/34412639 http://dx.doi.org/10.1186/s12951-021-00988-0 |
_version_ | 1783740268314361856 |
---|---|
author | Wang, Shan-Shan Liu, Zi-Kai Liu, Jing-Jing Cheng, Qing Wang, Yan-Xia Liu, Yan Ni, Wen-Wen Chen, Hong-Zhuan Song, Mingke |
author_facet | Wang, Shan-Shan Liu, Zi-Kai Liu, Jing-Jing Cheng, Qing Wang, Yan-Xia Liu, Yan Ni, Wen-Wen Chen, Hong-Zhuan Song, Mingke |
author_sort | Wang, Shan-Shan |
collection | PubMed |
description | BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological marker for predicting AD. However, this speculation remains to be explored with an appropriate assay method because mammalian AEP exists in many organs and the level of AEP in body fluid isn’t proportional to its concentration in brain parenchyma. To this end, we here modified gold nanoparticle (AuNPs) into an AEP-responsive imaging probe and choose transgenic APPswe/PS1dE9 (APP/PS1) mice as an animal model of AD. Our aim is to determine whether imaging of brain AEP can be used to predict AD pathology. RESULTS: This AEP-responsive imaging probe AuNPs-Cy5.5-A&C consisted of two particles, AuNPs-Cy5.5-AK and AuNPs-Cy5.5-CABT, which were respectively modified with Ala–Ala–Asn–Cys–Lys (AK) and 2-cyano-6-aminobenzothiazole (CABT). We showed that AuNPs-Cy5.5-A&C could be selectively activated by AEP to aggregate and emit strong fluorescence. Moreover, AuNPs-Cy5.5-A&C displayed a general applicability in various cell lines and its florescence intensity correlated well with AEP activity in these cells. In the brain of APP/PS1 transgenic mice , AEP activity was increased at an early disease stage of AD that precedes formation of senile plaques and cognitive impairment. Pharmacological inhibition of AEP with δ-secretase inhibitor 11 (10 mg kg(−1), p.o.) reduced production of β-amyloid (Aβ) and ameliorated memory loss. Therefore, elevation of AEP is an early sign of AD onset. Finally, we showed that live animal imaging with this AEP-responsive probe could monitor the up-regulated AEP in the brain of APP/PS1 mice. CONCLUSIONS: The current work provided a proof of concept that assessment of brain AEP activity by in vivo imaging assay is a potential biomarker for early diagnosis of AD. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00988-0. |
format | Online Article Text |
id | pubmed-8375181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83751812021-08-23 Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease Wang, Shan-Shan Liu, Zi-Kai Liu, Jing-Jing Cheng, Qing Wang, Yan-Xia Liu, Yan Ni, Wen-Wen Chen, Hong-Zhuan Song, Mingke J Nanobiotechnology Research BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological marker for predicting AD. However, this speculation remains to be explored with an appropriate assay method because mammalian AEP exists in many organs and the level of AEP in body fluid isn’t proportional to its concentration in brain parenchyma. To this end, we here modified gold nanoparticle (AuNPs) into an AEP-responsive imaging probe and choose transgenic APPswe/PS1dE9 (APP/PS1) mice as an animal model of AD. Our aim is to determine whether imaging of brain AEP can be used to predict AD pathology. RESULTS: This AEP-responsive imaging probe AuNPs-Cy5.5-A&C consisted of two particles, AuNPs-Cy5.5-AK and AuNPs-Cy5.5-CABT, which were respectively modified with Ala–Ala–Asn–Cys–Lys (AK) and 2-cyano-6-aminobenzothiazole (CABT). We showed that AuNPs-Cy5.5-A&C could be selectively activated by AEP to aggregate and emit strong fluorescence. Moreover, AuNPs-Cy5.5-A&C displayed a general applicability in various cell lines and its florescence intensity correlated well with AEP activity in these cells. In the brain of APP/PS1 transgenic mice , AEP activity was increased at an early disease stage of AD that precedes formation of senile plaques and cognitive impairment. Pharmacological inhibition of AEP with δ-secretase inhibitor 11 (10 mg kg(−1), p.o.) reduced production of β-amyloid (Aβ) and ameliorated memory loss. Therefore, elevation of AEP is an early sign of AD onset. Finally, we showed that live animal imaging with this AEP-responsive probe could monitor the up-regulated AEP in the brain of APP/PS1 mice. CONCLUSIONS: The current work provided a proof of concept that assessment of brain AEP activity by in vivo imaging assay is a potential biomarker for early diagnosis of AD. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00988-0. BioMed Central 2021-08-19 /pmc/articles/PMC8375181/ /pubmed/34412639 http://dx.doi.org/10.1186/s12951-021-00988-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wang, Shan-Shan Liu, Zi-Kai Liu, Jing-Jing Cheng, Qing Wang, Yan-Xia Liu, Yan Ni, Wen-Wen Chen, Hong-Zhuan Song, Mingke Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title | Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title_full | Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title_fullStr | Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title_full_unstemmed | Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title_short | Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease |
title_sort | imaging asparaginyl endopeptidase (aep) in the live brain as a biomarker for alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375181/ https://www.ncbi.nlm.nih.gov/pubmed/34412639 http://dx.doi.org/10.1186/s12951-021-00988-0 |
work_keys_str_mv | AT wangshanshan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT liuzikai imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT liujingjing imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT chengqing imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT wangyanxia imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT liuyan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT niwenwen imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT chenhongzhuan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease AT songmingke imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease |